Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. School of Public Health
  4. Department of Infectious Diseases
  5. Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
 
  • Details
Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
File(s)
1-s2.0-S2162253121001499-main.pdf (1.14 MB)
Published version
Author(s)
Aldon, Yoann
McKay, Paul F
Herrero, Jorge Moreno
Vogel, Annette B
Lévai, Réka
more
Type
Journal Article
Abstract
Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine immunogens. Unlike plasmid DNA, saRNA does not require entry into the nucleus of target cells for expression having the capacity to drive higher protein expression compared to mRNA as it replicates within the cytoplasm. In this study, we examined the potential of stabilized native-like HIV-1 Envelope glycoprotein (Env) trimers to elicit immune responses when delivered by saRNA polyplexes (PLX), assembled with linear polyethylenimine. We showed that Venezuelan equine encephalitis virus (VEEV) saRNA induces a stronger humoral immune response to the encoded transgene compared to Semliki Forest virus saRNA. Moreover, we characterized the immunogenicity of the soluble and membrane-bound ConSOSL.UFO Env design in mice and showed a faster humoral kinetic and an IgG2a skew using a membrane-bound design. The immune response generated by PLX VEEV saRNA encoding the membrane-bound Env was then evaluated in larger animal models including macaques in which low doses induced high IgG responses. Our data demonstrated that the VEEV saRNA PLX nanoparticle formulation represents a suitable platform for the delivery of stabilized HIV-1 Env and has the potential to be used in a variety of vaccine regimens.
Date Issued
2021-09-03
Date Acceptance
2021-06-16
Citation
Molecular Therapy - Nucleic Acids, 2021, 25, pp.483-493
URI
http://hdl.handle.net/10044/1/89998
URL
https://www.sciencedirect.com/science/article/pii/S2162253121001499?via%3Dihub
DOI
https://www.dx.doi.org/10.1016/j.omtn.2021.06.008
ISSN
2162-2531
Publisher
Elsevier BV
Start Page
483
End Page
493
Journal / Book Title
Molecular Therapy - Nucleic Acids
Volume
25
Copyright Statement
© 2021 The Authors. This work is published under CC BY-NC-ND license.
License URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
Commission of the European Communities
Identifier
https://www.sciencedirect.com/science/article/pii/S2162253121001499?via%3Dihub
Grant Number
681137
Subjects
Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Research & Experimental Medicine
EQUINE ENCEPHALITIS-VIRUS
DNA VACCINE
NONVIRAL DELIVERY
IMMUNE-RESPONSES
TYPE-1 ENVELOPE
NEUTRALIZING ANTIBODIES
IN-VITRO
T-CELLS
ELECTROPORATION
CHALLENGE
Env
HIV
PEI
macaque
mouse
polyplexes
saRNA
vaccine
0601 Biochemistry and Cell Biology
1103 Clinical Sciences
Publication Status
Published
Date Publish Online
2021-06-24
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback